QIAGEN NV EO -.01 news, videos and press releases
For more news please use our advanced search feature.
QIAGEN NV EO -.01 - More news...
QIAGEN NV EO -.01 - More news...
- QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million
- QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
- QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase
- EQS-Adhoc: QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase
- QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples
- QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care
- QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content
- QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data
- QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation
- QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing
- EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. launches non-US offering of net share settled convertible bonds
- EQS-Adhoc: QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase
- IGI Inex Holding (UK) Becomes Strategic Investor in Quantumrock, Cementing Partnership Between Leading Global Investment Group and AI Asset Tech Frontrunners
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces preliminary Q2 2021 results and updates 2021 outlook
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN to conduct an additional up to USD 100 million share repurchase program
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN N.V. launches non-U.S. offering of net share settled convertible bonds and solicits offers from non-U.S. holders to sell any and all of the outstanding convertible notes due 2021
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2020 outlook
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN reports strong preliminary results for third quarter of 2020
- DGAP-Adhoc: QIAGEN N.V.: Resignation of Chairman of the Supervisory Board
- DGAP-Adhoc: QIAGEN N.V.: Thermo Fisher to increase cash consideration and lower Acceptance Threshold in Offer for all shares of QIAGEN N.V.
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN provides outlook for third quarter and full-year 2020 as well as expectations for 2021
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces preliminary results for Q2 2020
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN provides information on potential capital gain from its minority investment in ArcherDX
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN expects higher results for Q2 2020 based on trends to date and suspends outlook for full-year 2020
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces preliminary Q1 2020 results
- DGAP-Adhoc: QIAGEN N.V.: Conclusion of a Business Combination Agreement between QIAGEN N.V. and Thermo Fisher Scientific Inc.; Announcement of a public tender offer by Thermo Fisher Scientific Inc.
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN concludes strategic alternatives review; decides to focus on stand-alone business strategy to drive future value creation
- DGAP-Adhoc: QIAGEN N.V.: QIAGEN receives several conditional, non-binding indications of interest, and decides to enter into discussions to explore potential strategic alterna-tives
